

SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED

PO Box 309, Uglan House
Grand Cayman, KY1-1104
Cayman Islands

SILVER PEGASUS INVESTMENT LIMITED

Walkers Corporate Limited
190 Elgin Avenue
George Town
Grand Cayman, KY1-9008
Cayman Islands

24 May 2024

Dear Sirs,

**(1) PROPOSAL FOR THE PRIVATISATION OF
SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED
BY SILVER PEGASUS INVESTMENT LIMITED
BY WAY OF A SCHEME OF ARRANGEMENT
(UNDER SECTION 86 OF THE COMPANIES ACT)**

**(2) PROPOSED WITHDRAWAL OF LISTING OF
SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED**

(3) SPECIAL DEAL RELATING TO ROLLOVER ARRANGEMENTS

We refer to the scheme document jointly issued by SciClone Pharmaceuticals (Holdings) Limited and Silver Pegasus Investment Limited dated 24 May 2024 in relation to, among other things, the captioned matters (the “**Scheme Document**”). Capitalised terms used in this letter shall have the same meanings as those defined in the Scheme Document, unless the context requires otherwise.

We, Opus Capital, as the Independent Financial Adviser to the Independent Board Committee, hereby confirm that we have given and have not withdrawn our written consent to the issue of the Scheme Document with the inclusion therein of the text of our advice, our letter dated 24 May 2024 to the Independent Board Committee, and the references to our name in the form and context in which they are included.

We hereby further consent to, and confirm that we have not withdrawn our written consent to, our letter dated 24 May 2024 to the Independent Board Committee and this letter being made available for public inspection as described in the section headed “10. Documents Available for Inspection” in Appendix II (General Information) to the Scheme Document.

Yours faithfully,

For and on behalf of
Opus Capital Limited

A handwritten signature in blue ink, appearing to be 'AK', is written over a horizontal line.

Name: CHEUNG On Kit Andrew
Title: Executive Director – Corporate Finance